[ 18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: Synthesis and in vivo evaluation in rhesus monkey

Nuclear Medicine and Biology

Volumn 38, Issue 8, 2011, Pages 1193-1203

  Hostetler, Eric D ^a   Sanabria Bohórquez, Sandra ^a   Fan, Hong ^a   Zeng, Zhizhen ^a   Gammage, Linda ^a   Miller, Patricia ^a   O'Malley, Stacey ^a   Connolly, Brett ^a   Mulhearn, James ^a   Harrison, Scott T ^a   Wolkenberg, Scott E ^a   Barrow, James C ^a   Williams, David L ^a   Hargreaves, Richard J ^a   Sur, Cyrille ^a   Cook, Jacquelynn J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alzheimer's disease; Amyloid plaque, PET; Fluorine 18; Monkey; White matter

Indexed keywords

AD 265 F 18; AD 269 F 18; AD 278 F 18; AV 45 F 18; BENZOXAZOLE DERIVATIVE; MK 3328 F 18; TRACER; UNCLASSIFIED DRUG; FLUORINE; MK 3328; MK-3328; OXAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SYNTHESIS; GRAY MATTER; HUMAN; HUMAN TISSUE; IC 50; IMAGE PROCESSING; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LIPOPHILICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RHESUS MONKEY; WHITE MATTER; ANIMAL; AUTORADIOGRAPHY; BRAIN; EVALUATION; MACACA MULATTA; METABOLISM; METHODOLOGY; PATHOLOGY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ALZHEIMER DISEASE; ANIMALS; AUTORADIOGRAPHY; BRAIN; FLUORINE RADIOISOTOPES; HUMANS; INHIBITORY CONCENTRATION 50; MACACA MULATTA; OXAZOLES; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 82655181973     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.04.004     Document Type: Article

References (38)

1. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3(3):186-191.
2. Pearl G.S. Diagnosis of Alzheimer's disease in a community hospital-based brain bank program. South Med J 1997, 90(7):720-722.
3. 18F-AV-45 (flobetapir F-18). J Nucl Med 2010, 51(6):913-920.
4. Roberson E.D., Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006, 314(5800):781-784.
5. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81(2):741-766.
6. Cai L.S., Innis R.B., Pike V.W. Radioligand development for PET imaging of beta-amyloid (AD)-current status. Curr Med Chem 2007, 14(1):19-52.
7. Fodero-Tavoletti M.T., Cappai R., McLean C.A., Pike K.E., Adlard P.A., Cowie T., et al. Amyloid imaging in Alzheimer's disease and other dementias. Brain Imaging Behav 2009, 3(3):246-261.
8. Furumoto S., Okamura N., Iwata R., Yanai K., Arai H., Kudo Y. Recent advances in the development of amyloid imaging agents. Curr Top Med Chem 2007, 7(18):1773-1789.
9. Nagren K., Halldin C., Rinne J.O. Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol I 2010, 37(8):1575-1593.
10. Kung H.F., Choi S.R., Qu W.C., Zhang W., Skovronsky D. F-18 stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. J Med Chem 2010, 53(3):933-941.
11. Klunk W.E., Engler H., Nordberg A., Wang Y.M., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55(3):306-319.
12. Choi S.R., Golding G., Zhuang Z.P., Zhang W., Lim N., Hefti F., et al. Preclinical properties of F-18-AV-45: a PET agent for A beta plaques in the brain. J Nucl Med 2009, 50(11):1887-1894.
13. 18F-AV-45) PET imaging of δ-amyloid plaques is highly correlated with histopathological assays at autopsy. J Nucl Med 2010, 51(S2):387.
14. Barrow J, Harrison S, Mulhearn J, Sur C, Williams D, Wolkenberg D. Novel substituted azabenzoxazoles. WO 2009/155017, 2009.
15. Harrison ST, Mulhearn J, Wolkenberg SE, Miller PJ, O'Malley SS, Zeng Z, et al. Synthesis and evaluation of 5-fluoro-2-aryloxazolo[5,4-b]pyridines as beta-amyloid PET ligands and the identification of MK-3328. ACS Medicinal Chemistry Letters 2011;in press.
16. Hostetler E.D., Hamill T., Francis B.E., Burns H.D. A versatile, commercially available automated synthesizer for the development and production of PET radiotracers. J Labelled Compd Rad 2001, 44:S1042-S1044.
17. Yamazaki M., Neway W.E., Ohe T., Chen I.W., Rowe J.F., Hochman J.H., et al. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 2001, 296(3):723-735.
18. Wong K.P., Feng D., Meikle S.R., Fulham M.J. Improved lesion localization in PET using cluster analysis. In: Brain imaging using PET 2002, 163-170. Academic Press, San Diego.
19. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cerebr Blood F Met 1996, 16(5):834-840.
20. Jin H., Di L. Permeability - in vitro assays for assessing drug transporter activity. Curr Drug Metab 2008, 9(9):911-920.
21. 18F]KF-K-222 - a comparative study. J Labelled Compd Rad 1999, 42(10):975-985.
22. 18F]F-PEB. Nucl Med Biol 2007, 34(8):1009-1017.
23. Duyckaerts C., Potier M.C., Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008, 115(1):5-38.
24. 11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol I 2005, 32(5):593-600.
25. Klunk W.E., Lopresti B.J., Debnath M.L., Holt D.P., Wang Y.M., Huang G.F., et al. Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid PET tracer, PIB, in the same manner as human brain amyloid. Neurobiol Aging 2004, 25:S232-S233.
26. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005, 25(46):10598-10606.
27. Sur C. Preclinical imaging of amyloid-δ plaque: in search of an animal model 2010, World Pharmaceutical Congress, Philadelphia (PA).
28. Rosen R.F., Walker L.C., Levine H. PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol Aging 2011, 32:223-234.
29. 18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. P Natl Acad Sci USA 2007, 104(23):9800-9805.
30. Hamill T.G., Sato N., Jitsuoka M., Tokita S., Sanabria S., Eng W., et al. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse 2009, 63(12):1122-1132.
31. Hamill TG, Eng W, Jennings A, Lewis R, Thomas S, Wood S, et al. The synthesis and preclinical evaluation in rhesus monkey of [18F]MK-6577 and [11C]CMPyPB glycine transporter 1 positron emission tomography radiotracers. Synapse In press, DOI:10.1002/syn.20842.
32. 18F]CFpyPB: dosimetry and brain quantification in human. J Nucl Med 2009, 50(S2):1211.
33. 11C]MK-8278 in human. J Nucl Med 2009, 50(S2):1212.
34. Lopresti B.J., Klunk W.E., Mathis C.A., Hoge J.A., Ziolko S.K., Lu X.L., et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005, 46(12):1959-1972.
35. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7(2):129-135.
36. 11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68(19):1603-1606.
37. Price J.C., Klunk W.E., Lopresti B.J., Lu X.L., Hoge J.A., Ziolko S.K., et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cerebr Blood F Met 2005, 25(11):1528-1547.
38. Giovacchini G., Conant S., Herscovitch P., Theodore W.H. Using cerebral white matter for estimation of nondisplaceable binding of 5-HT1A receptors in temporal lobe epilepsy. J Nucl Med 2009, 50(11):1794-1800.